Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia

AbuRuz, Salah; Albekairy, Abdulkareem M; Alqahtani, Abdulaziz; Harbi, Khalid; Nuhait, Mohammed Al; Khoja, Abdullah T; Sadeq, Adel; Rashed, Mohammed Al

doi:10.1016/j.jsha.2018.08.003

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies presented the major explanations for statin refractoriness reported by healthcare practitioners, and patients were concerned about adverse events [12,[28][29][30][31][32][33]. Rosenson, R. S 2016 stated that evaluation of potential adverse events requires validated tools to differentiate between statin-associated adverse events versus nonspecific complaints.…”

Section: Discussionmentioning

confidence: 99%

Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management

et al. 2023

View full text Add to dashboard Cite

Objectives The study aims to examine the extent to which the updated ACC/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians’ adherence the guidelines recommendations. Methods We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists’ interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy. Results Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p<0.0001) and from 0.0% to 1.6% (X2 = 6, p = 0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2 = 19.2, p<0.0001). Conclusion Collaboration between physicians and clinical pharmacists is a crucial strategy to improve patients’ treatment and hence, achieve better health outcomes among patients suffering from dyslipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Several studies presented the major explanations for statin refractoriness reported by healthcare practitioners, and patients were concerns about adverse events (9,(22)(23)(24)(25)(26)(27). Rosenson, R. S ( 2016) stated that evaluation of potential adverse events requires validated tools to differentiate between statin-associated adverse events versus nonspeci c complaints.…”

Section: Discussionmentioning

confidence: 99%

Value of the Clinical Pharmacist Interventions in the Application of the American College of Cardiology (ACC/AHA) 2018 Guideline for Cholesterol Management

AlAhmad

Zain

et al. 2021

Preprint

View full text Add to dashboard Cite

The study aims to examine the extent of implementing the ACC/AHA cholesterol guideline and its updates in practice as well as the role of clinical pharmacists in making such guidelines effective. A cross-sectional observational study was conducted on 272 adult patients who visited the hospital internal medicine clinic in the UAE and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Clinical pharmacist interventions were determined. The chi-square test was used to compare compliance with the guidelines before and after clinical pharmacist interventions. Compliance with the recommendations for cholesterol management was significantly improved from 60.3% to 92.6% (X2=79.1, p=0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2=72.5, p=0.0001). The combination of statins with nonstatin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2=95, p<0.0001) and from 0.0% to 1.6% (X2=6, p=0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2=19.2, p<0.0001). Collaboration between physicians and clinical pharmacists is a crucial strategy to achieve better health outcomes among patients suffering from dyslipidemia.

show abstract

“…Nationwide studies conducted in the United States found that approximately 15%–40% of prescribed statins adhered to the most recent guidelines, particularly the latest ACC/AHA Guideline ( 12 , 13 ). In Saudi Arabia, the adherence rate ranged from 10% to 75%, whereas in Malaysia, it ranged between 40% and 50% ( 14 , 15 ). The adherence rates to guidelines differ across countries.…”

Section: Introductionmentioning

confidence: 99%

Adherence to the 2018 AHA cholesterol management guideline in hyperlipidemia treatment among adults in an outpatient setting

Behdani,

Kazemi,

Zardast

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAlthough evidence-based guidelines and effective treatments exist for dyslipidemia, a significant disparity remains between guidelines and clinical practice. In this study, we investigated adherence to statin therapy per the 2018 ACC/AHA Guideline recommendations.MethodsThis is a retrospective, descriptive-analytical study involving 1,224 individuals who presented to the laboratories located in Birjand, Eastern Iran, from June 2022 to March 2023. Analyses were conducted on 700 patients. Data collection utilized a checklist and serum value measurements of laboratory factors deemed necessary for the study.ResultsTreatment was administered per the guidelines for 348 out of the 700 patients (49.7%). With 60.7%, the diabetes group exhibited the highest level of adherence to guidelines. In the atherosclerotic cardiovascular disease (ASCVD) group, 31.7% followed the recommendations. The lowest adherence rates were in groups with a 10-year ASCVD risk score of ≥20% and severe hypercholesterolemia, respectively (0% and 2.8%). In our study, atorvastatin was the most frequently prescribed statin, with the majority of patients consuming a moderate-intensity statin. None of the severely hypercholesterolemic patients achieved the LDL goal. Moreover, LDL-C goal achievement was low among the ASCVD group and those with an ASCVD risk score of ≥20%.ConclusionPatients with hypercholesterolemia adhere inadequately to the AHA Guideline. Consequently, training courses are needed to inform medical doctors, particularly general practitioners, of the latest dyslipidemia treatment recommendations as the AHA advises.

show abstract

Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia

Cited by 4 publications

References 23 publications

Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management

Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management

Value of the Clinical Pharmacist Interventions in the Application of the American College of Cardiology (ACC/AHA) 2018 Guideline for Cholesterol Management

Adherence to the 2018 AHA cholesterol management guideline in hyperlipidemia treatment among adults in an outpatient setting

Contact Info

Product

Resources

About